FTLF - NASDAQ
FitLife Brands, Inc.
$10.00
+0.91%FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. It offers weight loss, general health, and sports nutrition supplements; precision sports nutrition formulations for professional muscular development; weight loss and sports nutrition performance enhancing supplements for fitness enthusiasts; and men's health and weight loss formulations, as well as other diet, health, and sports nutrition supplements and related products; and sports nutritional products, energy and weight loss products, and meal replacements. It markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Metis Nutrition, iSatori, BioGenetic Laboratories, and Energize through franchised stores, as well as through various retail locations, including specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.
At a Glance
Live SnapshotFitLife Brands, Inc. Management Team
Mr. Dayton Robert Judd CPA
Chairman & Chief Executive Officer
Compensation
$578,000
Mr. Jakob York
Chief Financial Officer
Compensation
$244,616
Ms. Jenna E. Sinnett
Chief Operating Officer
Compensation
$198,695
Mr. Patrick Ryan
Chief Retail Officer
Compensation
$295,953
Mr. Ryan Hansen
Executive Vice President
Compensation
$303,692
FitLife Brands, Inc. Insider Positioning
During the last 12 months, insiders have purchased $137K worth of FTLF shares, with no selling activity reported.
3 Months
6.0K
59.22K
0
0.00
+59K
+$59K
3-6 Months
164
2.52K
0
0.00
+3K
+$3K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
4.0K
74.92K
0
0.00
+75K
+$75K
Top Buyers
York Jakob
Officer: Chief Financial Officer
$75K
Dawson Grant Robert
Director
$30K
Lingenbrink Matthew
Director
$29K
Yakatan Seth
Director
$3K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $137K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
4 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
FTLF - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | June 24, 2025 | August 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | July 05, 2024 | August 13, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | June 30, 2023 | August 09, 2023 | 2023 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | June 08, 2021 | 2021 | |
DEF 14A DEF 14A 2019 N/A | July 12, 2019 | August 16, 2019 | 2019 | |
DEF 14A DEF 14A 2017 N/A | May 01, 2017 | May 01, 2017 | 2017 | |
DEF 14A DEF 14A 2015 N/A | April 30, 2015 | April 30, 2015 | 2015 | |
DEF 14A DEF 14A 2014 N/A | May 29, 2014 | May 27, 2014 | 2014 | |
DEF 14A DEF 14A 2013 N/A | June 12, 2013 | June 12, 2013 | 2013 | |
DEF 14A DEF 14A 2010 N/A | July 28, 2010 | August 26, 2010 | 2010 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.